Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$179.33
al cierre: Oct 3, 4:00 PM EDT
$179.33
0.000.00%
Pre-comercialización: Oct 3, 4:00 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Quest Diagnostics Inc ha un obiettivo di prezzo di consenso pari a $176.05, stabilito in base alle ultime valutazioni degli analisti di 20. Le ultime 3 valutazioni degli analisti sono state rilasciate da Barclays, Baird y UBS il octubre 2, 2025, agosto 25, 2025 y julio 23, 2025. Con un obiettivo di prezzo medio di $188 tra le Barclays, Baird y UBS, c'è un implicito 4.83% upside per Quest Diagnostics Inc da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Barclays
Baird
UBS
Truist Securities
Deutsche Bank
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Quest Diagnostics
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/02/2025 | 5.95% | Barclays | $185 → $190 | Maintains | Equal-Weight | |||
08/25/2025 | 8.18% | Baird | $194 → $194 | Downgrade | Outperform → Neutral | |||
07/23/2025 | 0.37% | UBS | $175 → $180 | Maintains | Neutral | |||
07/23/2025 | 7.07% | Truist Securities | $190 → $192 | Maintains | Hold | |||
07/23/2025 | -0.74% | Deutsche Bank | $160 → $178 | Maintains | Hold | |||
07/18/2025 | -2.41% | UBS | $176 → $175 | Maintains | Neutral | |||
05/06/2025 | 5.95% | JP Morgan | $180 → $190 | Maintains | Neutral | |||
04/28/2025 | 11.53% | Piper Sandler | $180 → $200 | Maintains | Neutral | |||
04/23/2025 | 5.95% | Truist Securities | $182 → $190 | Maintains | Hold | |||
04/23/2025 | 3.16% | Barclays | $175 → $185 | Maintains | Equal-Weight | |||
04/23/2025 | 0.37% | Evercore ISI Group | $175 → $180 | Maintains | In-Line | |||
04/23/2025 | 8.18% | Baird | $191 → $194 | Maintains | Outperform | |||
04/09/2025 | 5.39% | Mizuho | $178 → $189 | Maintains | Outperform | |||
04/02/2025 | 8.74% | Redburn Atlantic | → $195 | Initiates | → Buy | |||
03/20/2025 | 6.51% | Baird | $190 → $191 | Maintains | Outperform | |||
03/04/2025 | 3.16% | Citigroup | $185 → $185 | Downgrade | Buy → Neutral | |||
02/04/2025 | 0.37% | JP Morgan | $173 → $180 | Maintains | Neutral | |||
02/03/2025 | -0.74% | Mizuho | $177 → $178 | Maintains | Outperform | |||
02/03/2025 | -5.2% | UBS | $166 → $170 | Maintains | Neutral | |||
02/03/2025 | 0.37% | Piper Sandler | $165 → $180 | Reiterates | Neutral → Neutral | |||
01/31/2025 | 1.49% | Truist Securities | $172 → $182 | Maintains | Hold | |||
01/31/2025 | -2.41% | Barclays | $168 → $175 | Maintains | Equal-Weight | |||
01/06/2025 | -2.97% | Leerink Partners | $169 → $174 | Upgrade | Market Perform → Outperform | |||
12/23/2024 | -1.3% | Mizuho | $174 → $177 | Maintains | Outperform | |||
12/17/2024 | -4.09% | Morgan Stanley | $145 → $172 | Upgrade | Equal-Weight → Overweight | |||
12/13/2024 | 1.49% | B of A Securities | $179 → $182 | Maintains | Buy | |||
12/10/2024 | 3.16% | Jefferies | → $185 | Assumes | Buy → Buy | |||
10/28/2024 | -7.99% | Piper Sandler | $150 → $165 | Maintains | Neutral | |||
10/24/2024 | -2.97% | Mizuho | $160 → $174 | Maintains | Outperform | |||
10/23/2024 | -4.09% | Truist Securities | $165 → $172 | Maintains | Hold | |||
10/23/2024 | -7.43% | UBS | $165 → $166 | Maintains | Neutral | |||
10/23/2024 | 3.16% | Citigroup | $165 → $185 | Maintains | Buy | |||
10/23/2024 | -6.32% | Barclays | $154 → $168 | Maintains | Equal-Weight | |||
10/23/2024 | 1.49% | Baird | $157 → $182 | Upgrade | Neutral → Outperform | |||
10/07/2024 | -7.99% | Truist Securities | $158 → $165 | Maintains | Hold | |||
08/28/2024 | -7.99% | Evercore ISI Group | → $165 | Reinstates | → In-Line | |||
08/27/2024 | -14.12% | Barclays | $144 → $154 | Maintains | Equal-Weight | |||
07/29/2024 | -16.36% | Piper Sandler | $145 → $150 | Maintains | Neutral | |||
07/24/2024 | -14.12% | Baird | $153 → $154 | Maintains | Neutral | |||
07/15/2024 | -11.89% | Truist Securities | $150 → $158 | Maintains | Hold | |||
07/10/2024 | -7.99% | Citigroup | $145 → $165 | Upgrade | Neutral → Buy | |||
07/05/2024 | -14.68% | Baird | $145 → $153 | Maintains | Neutral | |||
05/30/2024 | -13.57% | JP Morgan | $152 → $155 | Maintains | Neutral | |||
04/25/2024 | -19.7% | Barclays | $138 → $144 | Maintains | Equal-Weight | |||
04/24/2024 | -19.14% | Citigroup | $135 → $145 | Maintains | Neutral | |||
04/24/2024 | -18.59% | UBS | $139 → $146 | Maintains | Neutral | |||
04/24/2024 | -16.36% | Truist Securities | $145 → $150 | Maintains | Hold | |||
04/24/2024 | -13.57% | Mizuho | $150 → $155 | Maintains | Buy | |||
03/20/2024 | -19.14% | Truist Securities | → $145 | Reiterates | Hold → Hold | |||
02/26/2024 | -24.72% | Leerink Partners | → $135 | Initiates | → Market Perform | |||
02/07/2024 | -13.57% | Jefferies | $140 → $155 | Upgrade | Hold → Buy | |||
02/02/2024 | -19.14% | Truist Securities | $150 → $145 | Maintains | Hold | |||
12/20/2023 | -16.36% | Truist Securities | $145 → $150 | Maintains | Hold | |||
12/12/2023 | -10.78% | B of A Securities | $140 → $160 | Upgrade | Neutral → Buy | |||
12/11/2023 | -19.14% | Citigroup | $130 → $145 | Maintains | Neutral | |||
12/07/2023 | -23.6% | UBS | $135 → $137 | Maintains | Neutral | |||
11/17/2023 | -16.91% | JP Morgan | $148 → $149 | Maintains | Neutral | |||
11/06/2023 | -21.93% | Piper Sandler | $130 → $140 | Maintains | Neutral | |||
10/25/2023 | -27.51% | Citigroup | $142 → $130 | Maintains | Neutral | |||
10/16/2023 | -27.51% | Piper Sandler | $145 → $130 | Maintains | Neutral | |||
08/03/2023 | -19.14% | Morgan Stanley | $145 → $145 | Reiterates | Equal-Weight → Equal-Weight | |||
06/29/2023 | -19.14% | Piper Sandler | → $145 | Initiates | → Neutral | |||
05/10/2023 | -19.14% | Morgan Stanley | $158 → $145 | Maintains | Equal-Weight | |||
05/02/2023 | -17.47% | B of A Securities | $166 → $148 | Downgrade | Buy → Neutral | |||
04/03/2023 | -20.82% | Citigroup | $125 → $142 | Upgrade | Sell → Neutral | |||
03/17/2023 | -10.78% | Truist Securities | $170 → $160 | Maintains | Hold | |||
03/17/2023 | -7.99% | Mizuho | → $165 | Reiterates | → Buy | |||
02/03/2023 | -21.93% | Wells Fargo | $135 → $140 | Maintains | Equal-Weight | |||
01/25/2023 | -18.59% | Credit Suisse | $143 → $146 | Maintains | Neutral | |||
01/23/2023 | -11.34% | Evercore ISI Group | → $159 | Initiates | → In-Line | |||
01/12/2023 | -14.12% | Baird | $143 → $154 | Maintains | Neutral | |||
01/06/2023 | -11.89% | Morgan Stanley | $146 → $158 | Maintains | Equal-Weight | |||
12/14/2022 | -7.99% | Mizuho | $160 → $165 | Maintains | Buy | |||
11/17/2022 | -30.3% | Citigroup | $145 → $125 | Downgrade | Neutral → Sell | |||
10/21/2022 | -18.59% | Morgan Stanley | $142 → $146 | Maintains | Equal-Weight | |||
10/21/2022 | -21.93% | Deutsche Bank | $129 → $140 | Maintains | Hold |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Quest Diagnostics (DGX)?
El último precio objetivo de Quest Diagnostics (NYSE:DGX) fue comunicado por Barclays el octubre 2, 2025. La firma de analistas fijó un precio objetivo para $190.00 que espera DGX a rise dentro de 12 meses (un posible 5.95% upside). 35 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Quest Diagnostics (DGX)?
La última calificación de analistas para Quest Diagnostics (NYSE:DGX) fue proporcionada por Barclays, y Quest Diagnostics mantuvo su equal-weight calificación.
¿Cuándo se produjo la última revisión al alza de Quest Diagnostics (DGX)?
La última revisión al alza de Quest Diagnostics Inc se produjo en enero 6, 2025, cuando Leerink Partners elevó su precio objetivo a $174. Leerink Partners anteriormente tenía a market perform para Quest Diagnostics Inc.
¿Cuándo fue la última revisión a la baja de Quest Diagnostics (DGX)?
La última revisión a la baja de Quest Diagnostics Inc se produjo en agosto 25, 2025, cuando Baird cambió su precio objetivo de $194 a $194 para Quest Diagnostics Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Quest Diagnostics (DGX)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Quest Diagnostics, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Quest Diagnostics se registró el octubre 2, 2025, por lo que la próxima calificación estará disponible en torno al octubre 2, 2026.
¿Es correcta la calificación de los analistas sobre Quest Diagnostics (DGX)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Quest Diagnostics (DGX) fue un mantuvo con un precio objetivo de $185.00 a $190.00. El precio actual al que cotiza Quest Diagnostics (DGX) es de $179.33, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.